Literature DB >> 8676346

Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs.

B H Norman1, C Shih, J E Toth, J E Ray, J A Dodge, D W Johnson, P G Rutherford, R M Schultz, J F Worzalla, C J Vlahos.   

Abstract

Wortmannin, a fungal metabolite, was identified as a potent inhibitor (IC50 = 4.2 nM) of phosphatidylinositol 3-kinase (PI 3-kinase). Due to the importance of PI 3-kinase in several intracellular signaling pathways, structure-activities studies on wortmannin analogs were performed in an effort to understand the structural requirements necessary for PI 3-kinase inhibition. Since wortmannin is an irreversible inhibitor of PI 3-kinase, it was postulated that covalent attachment at the electrophilic C-21 site was a possible mode of action for PI 3-kinase inhibition. We have prepared various wortmannin analogs which address the possibility of this mechanism. Of particular interest are compounds which affect the C-21 position of wortaminnin either sterically or electronically. Our results support the conclusion that nucleophilic addition by the kinase onto the C-21 position of wortmannin is required for inhibition of PI 3-kinase by wortmannin analogs. Additionally, we have prepared several D-ring analogs of wortmannin, and their activities are reported herein. We conclude that the wortmannin D ring is an important recognition site since modifications have such a dramatic effect on inhibitor potency. Finally, the identification of 17beta-hydroxywortmannin represents the first reported subnanomolar inhibitor of PI 3-kinase. These studies, along with in vivo antitumor experiments, suggest that the mechanism of PI 3-kinase inhibition correlates to the associated toxicity observed with wortmannin-based inhibitors of PI 3-kinase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8676346     DOI: 10.1021/jm950619p

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  25 in total

1.  Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region.

Authors:  Pietro Paolo Sanna; Maurizio Cammalleri; Fulvia Berton; Cindy Simpson; Robert Lutjens; Floyd E Bloom; Walter Francesconi
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

2.  A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling.

Authors:  Mariko Hatakeyama; Shuhei Kimura; Takashi Naka; Takuji Kawasaki; Noriko Yumoto; Mio Ichikawa; Jae-Hoon Kim; Kazuki Saito; Mihoro Saeki; Mikako Shirouzu; Shigeyuki Yokoyama; Akihiko Konagaya
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

3.  Hepatocyte entry leads to degradation of autoreactive CD8 T cells.

Authors:  Volker Benseler; Alessandra Warren; Michelle Vo; Lauren E Holz; Szun S Tay; David G Le Couteur; Eamon Breen; Anthony C Allison; Nico van Rooijen; Claire McGuffog; Hans J Schlitt; David G Bowen; Geoffrey W McCaughan; Patrick Bertolino
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-20       Impact factor: 11.205

Review 4.  Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.

Authors:  Nathan T Ihle; Garth Powis
Journal:  Mol Aspects Med       Date:  2010-02-20

5.  Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways.

Authors:  Zhao Zhong Chong; Jing-Qiong Kang; Kenneth Maiese
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

6.  Strategies for the Synthesis of the Halenaquinol and Xestoquinol Families of Natural Products.

Authors:  Gregg M Schwarzwalder; Christopher D Vanderwal
Journal:  European J Org Chem       Date:  2017-02-16

7.  Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.

Authors:  Dima A Sabbah; Jonathan L Vennerstrom; Haizhen Zhong
Journal:  J Chem Inf Model       Date:  2010-10-25       Impact factor: 4.956

Review 8.  Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment.

Authors:  Pau Castel; Eneda Toska; Zachary S Zumsteg; F Javier Carmona; Moshe Elkabets; Ana Bosch; Maurizio Scaltriti
Journal:  Mol Cell Oncol       Date:  2014-10-29

9.  Evaluating PI3 kinase isoforms using Transcreener ADP assays.

Authors:  Tony A Klink; Karen M Kleman-Leyer; Andrew Kopp; Thane A Westermeyer; Robert G Lowery
Journal:  J Biomol Screen       Date:  2008-06-19

Review 10.  Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design.

Authors:  Sandra B Gabelli; Diana Mandelker; Oleg Schmidt-Kittler; Bert Vogelstein; L Mario Amzel
Journal:  Biochim Biophys Acta       Date:  2009-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.